Taken together, this exploratory analysis of LEADER and SUSTAIN-6 trials suggests that the renoprotection afforded by GLP-1 receptor agonists is likely more pronounced in patients with T2DM and pre-existing CKD than in those with preserved kidney function. This evidence concerns the gene GLP1R and chronic kidney disease.